EUFOREA consensus on biologics for CRSwNP with or without asthma

被引:292
作者
Fokkens, Wytske J. [1 ,2 ]
Lund, Valerie [3 ]
Bachert, Claus [2 ,4 ,5 ,6 ]
Mullol, Joaquim [7 ]
Bjermer, Leif [8 ]
Bousquet, Jean [2 ,9 ]
Canonica, Giorgio W. [10 ,11 ]
Deneyer, Lauren [2 ]
Desrosiers, Martin [12 ]
Diamant, Zuzana [8 ,13 ,14 ,15 ,16 ,17 ]
Han, Joseph [18 ]
Heffler, Enrico [10 ,11 ]
Hopkins, Claire [19 ]
Jankowski, Roger [20 ]
Joos, Guy [21 ]
Knill, Andrew [22 ]
Lee, Jivianne [23 ]
Lee, Stella E. [24 ]
Marien, Gert [2 ]
Pugin, Benoit [2 ,25 ]
Senior, Brent [26 ]
Seys, Sven F. [2 ,25 ]
Hellings, Peter W. [1 ,2 ,25 ,27 ]
机构
[1] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, Locat AMC Amsterdam, Amsterdam, Netherlands
[2] European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium
[3] Univ Coll London Hosp, Royal Natl Throat Nose & Ear Hosp, London, England
[4] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium
[5] Karolinska Univ Hosp, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden
[6] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden
[7] Univ Barcelona, Hosp Clin, Dept Otorhinolaryngol, CIBERES,IDIBAPS, Barcelona, Catalonia, Spain
[8] Lund Univ, Dept Resp Med & Allergol, Lund, Sweden
[9] Univ Hosp Arnaud de Villeneuve, Dept Resp Dis, Montpellier, France
[10] IRCCS, Personalized Med Asthma & Allergy Humanitas Clin, Rozzano, MI, Italy
[11] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy
[12] Univ Montreal Hosp Ctr CHUM, Div Otolaryngol Head & Neck Surg, Montreal, PQ, Canada
[13] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[14] Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands
[15] QPS NL, Groningen, Netherlands
[16] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic
[17] Thomayer Hosp, Prague, Czech Republic
[18] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA
[19] Guys & St Thomas NHS Fdn Trust, London, England
[20] Univ Hosp Nancy, ENT Dept, Brabois ILM, Nancy, France
[21] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium
[22] Opuscomms, London, England
[23] Univ Calif Los Angeles, Dept Head & Neck Surg, Rhinol & Endoscop Skull Base Surg, Los Angeles, CA USA
[24] Univ Pittsburgh, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Sinonasal Disorders & Allergy, Pittsburgh, PA 15261 USA
[25] Dept Microbiol Immunol & Transplantat, Allergy & Clin Immunol Res Grp, Leuven, Belgium
[26] Univ North Carolina Chapel Hill, Div Rhinol Allergy & Endoscop Skull Base Surg, Chapel Hill, NC USA
[27] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium
关键词
asthma; biologics; chronic rhinosinusitis; nasal polyps; type; 2; inflammation; ENDOSCOPIC SINUS SURGERY; ADULT CHRONIC RHINOSINUSITIS; NATIONAL COMPARATIVE AUDIT; QUALITY-OF-LIFE; NASAL POLYPOSIS; OMALIZUMAB; PREVALENCE; MANAGEMENT; ALLERGY; CORTICOSTEROIDS;
D O I
10.1111/all.13875
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4R alpha, anti-IL5, and anti-IL5R alpha have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
引用
收藏
页码:2312 / 2319
页数:8
相关论文
共 77 条
[1]   Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug [J].
Asero, Riccardo .
ALLERGY, 2018, 73 (11) :2242-2244
[2]   Endotype-driven care pathways in patients with chronic rhinosinusitis [J].
Bachert, Claus ;
Zhang, Nan ;
Hellings, Peter W. ;
Bousquet, Jean .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (05) :1543-1551
[3]   Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial [J].
Bachert, Claus ;
Mannent, Leda ;
Naclerio, Robert M. ;
Mullol, Joaquim ;
Ferguson, Berrylin J. ;
Gevaert, Philippe ;
Hellings, Peter ;
Jiao, Lixia ;
Wang, Lin ;
Evans, Robert R. ;
Pirozzi, Gianluca ;
Graham, Neil M. ;
Swanson, Brian ;
Hamilton, Jennifer D. ;
Radin, Allen ;
Gandhi, Namita A. ;
Stahl, Neil ;
Yancopoulos, George D. ;
Sutherland, E. Rand .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05) :469-479
[4]   Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial [J].
Bachert, Claus ;
Sousa, Ana R. ;
Lund, Valerie J. ;
Scadding, Glenis K. ;
Gevaert, Philippe ;
Nasser, Shuaib ;
Durham, Stephen R. ;
Cornet, Marjolein E. ;
Kariyawasam, Harsha H. ;
Gilbert, Jane ;
Austin, Daren ;
Maxwell, Aoife C. ;
Marshall, Richard P. ;
Fokkens, Wytske J. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (04) :1024-+
[5]   Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis [J].
Bachert, Claus ;
Zhang, Luo ;
Gevaert, Phillippe .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (06) :1431-1440
[6]  
Bidder T, 2018, RHINOLOGY, V56, P42, DOI [10.4193/Rhin17.139, 10.4193/Rhino17.139]
[7]   Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Gooderham, Melinda ;
Cather, Jennifer C. ;
Weisman, Jamie ;
Pariser, David ;
Simpson, Eric L. ;
Papp, Kim A. ;
Hong, H. Chih-Ho ;
Rubel, Diana ;
Foley, Peter ;
Prens, Errol ;
Griffiths, Christopher E. M. ;
Etoh, Takafumi ;
Pinto, Pedro Herranz ;
Pujol, Ramon M. ;
Szepietowski, Jacek C. ;
Ettler, Karel ;
Kemeny, Lajos ;
Zhu, Xiaoping ;
Akinlade, Bolanle ;
Hultsch, Thomas ;
Mastey, Vera ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Amin, Nikhil ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Stahl, Neil ;
Yancopoulos, George D. ;
Shumel, Brad .
LANCET, 2017, 389 (10086) :2287-2303
[8]   Anti-immunoglobulin E (omalizumab) therapy in allergic asthma [J].
Busse, WW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (08) :S12-S17
[9]   Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma [J].
Castro, M. ;
Corren, J. ;
Pavord, I. D. ;
Maspero, J. ;
Wenzel, S. ;
Rabe, K. F. ;
Busse, W. W. ;
Ford, L. ;
Sher, L. ;
FitzGerald, J. M. ;
Katelaris, C. ;
Tohda, Y. ;
Zhang, B. ;
Staudinger, H. ;
Pirozzi, G. ;
Amin, N. ;
Ruddy, M. ;
Akinlade, B. ;
Khan, A. ;
Chao, J. ;
Martincova, R. ;
Graham, N. M. H. ;
Hamilton, J. D. ;
Swanson, B. N. ;
Stahl, N. ;
Yancopoulos, G. D. ;
Teper, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) :2486-2496
[10]   International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [J].
Chung, Kian Fan ;
Wenzel, Sally E. ;
Brozek, Jan L. ;
Bush, Andrew ;
Castro, Mario ;
Sterk, Peter J. ;
Adcock, Ian M. ;
Bateman, Eric D. ;
Bel, Elisabeth H. ;
Bleecker, Eugene R. ;
Boulet, Louis-Philippe ;
Brightling, Christopher ;
Chanez, Pascal ;
Dahlen, Sven-Erik ;
Djukanovic, Ratko ;
Frey, Urs ;
Gaga, Mina ;
Gibson, Peter ;
Hamid, Qutayba ;
Jajour, Nizar N. ;
Mauad, Thais ;
Sorkness, Ronald L. ;
Teague, W. Gerald .
EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) :343-373